Cargando…

A comprehensive review of COVID-19 characteristics

In December 2019, a novel coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) with unknown origin spread in Hubei province of China. The epidemic disease caused by SARS-CoV-2 called coronavirus disease-19 (COVID-19). The presence of COVID-19 was manifested...

Descripción completa

Detalles Bibliográficos
Autores principales: Esakandari, Hanie, Nabi-Afjadi, Mohsen, Fakkari-Afjadi, Javad, Farahmandian, Navid, Miresmaeili, Seyed-Mohsen, Bahreini, Elham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402395/
https://www.ncbi.nlm.nih.gov/pubmed/32774178
http://dx.doi.org/10.1186/s12575-020-00128-2
_version_ 1783566749182984192
author Esakandari, Hanie
Nabi-Afjadi, Mohsen
Fakkari-Afjadi, Javad
Farahmandian, Navid
Miresmaeili, Seyed-Mohsen
Bahreini, Elham
author_facet Esakandari, Hanie
Nabi-Afjadi, Mohsen
Fakkari-Afjadi, Javad
Farahmandian, Navid
Miresmaeili, Seyed-Mohsen
Bahreini, Elham
author_sort Esakandari, Hanie
collection PubMed
description In December 2019, a novel coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) with unknown origin spread in Hubei province of China. The epidemic disease caused by SARS-CoV-2 called coronavirus disease-19 (COVID-19). The presence of COVID-19 was manifested by several symptoms, ranging from asymptomatic/mild symptoms to severe illness and death. The viral infection expanded internationally and WHO announced a Public Health Emergency of International Concern. To quickly diagnose and control such a highly infectious disease, suspicious individuals were isolated and diagnostic/treatment procedures were developed through patients’ epidemiological and clinical data. Early in the COVID-19 outbreak, WHO invited hundreds of researchers from around the world to develop a rapid quality diagnosis, treatment and vaccines, but so far no specific antiviral treatment or vaccine has been approved by the FDA. At present, COVID-19 is managed by available antiviral drugs to improve the symptoms, and in severe cases, supportive care including oxygen and mechanical ventilation is used for infected patients. However, due to the worldwide spread of the virus, COVID-19 has become a serious concern in the medical community. According to the current data of WHO, the number of infected and dead cases has increased to 8,708,008 and 461,715, respectively (Dec 2019 –June 2020). Given the high mortality rate and economic damage to various communities to date, great efforts must be made to produce successful drugs and vaccines against 2019-nCoV infection. For this reason, first of all, the characteristics of the virus, its pathogenicity, and its infectious pathways must be well known. Thus, the main purpose of this review is to provide an overview of this epidemic disease based on the current evidence.
format Online
Article
Text
id pubmed-7402395
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74023952020-08-05 A comprehensive review of COVID-19 characteristics Esakandari, Hanie Nabi-Afjadi, Mohsen Fakkari-Afjadi, Javad Farahmandian, Navid Miresmaeili, Seyed-Mohsen Bahreini, Elham Biol Proced Online Review In December 2019, a novel coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) with unknown origin spread in Hubei province of China. The epidemic disease caused by SARS-CoV-2 called coronavirus disease-19 (COVID-19). The presence of COVID-19 was manifested by several symptoms, ranging from asymptomatic/mild symptoms to severe illness and death. The viral infection expanded internationally and WHO announced a Public Health Emergency of International Concern. To quickly diagnose and control such a highly infectious disease, suspicious individuals were isolated and diagnostic/treatment procedures were developed through patients’ epidemiological and clinical data. Early in the COVID-19 outbreak, WHO invited hundreds of researchers from around the world to develop a rapid quality diagnosis, treatment and vaccines, but so far no specific antiviral treatment or vaccine has been approved by the FDA. At present, COVID-19 is managed by available antiviral drugs to improve the symptoms, and in severe cases, supportive care including oxygen and mechanical ventilation is used for infected patients. However, due to the worldwide spread of the virus, COVID-19 has become a serious concern in the medical community. According to the current data of WHO, the number of infected and dead cases has increased to 8,708,008 and 461,715, respectively (Dec 2019 –June 2020). Given the high mortality rate and economic damage to various communities to date, great efforts must be made to produce successful drugs and vaccines against 2019-nCoV infection. For this reason, first of all, the characteristics of the virus, its pathogenicity, and its infectious pathways must be well known. Thus, the main purpose of this review is to provide an overview of this epidemic disease based on the current evidence. BioMed Central 2020-08-04 /pmc/articles/PMC7402395/ /pubmed/32774178 http://dx.doi.org/10.1186/s12575-020-00128-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Esakandari, Hanie
Nabi-Afjadi, Mohsen
Fakkari-Afjadi, Javad
Farahmandian, Navid
Miresmaeili, Seyed-Mohsen
Bahreini, Elham
A comprehensive review of COVID-19 characteristics
title A comprehensive review of COVID-19 characteristics
title_full A comprehensive review of COVID-19 characteristics
title_fullStr A comprehensive review of COVID-19 characteristics
title_full_unstemmed A comprehensive review of COVID-19 characteristics
title_short A comprehensive review of COVID-19 characteristics
title_sort comprehensive review of covid-19 characteristics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402395/
https://www.ncbi.nlm.nih.gov/pubmed/32774178
http://dx.doi.org/10.1186/s12575-020-00128-2
work_keys_str_mv AT esakandarihanie acomprehensivereviewofcovid19characteristics
AT nabiafjadimohsen acomprehensivereviewofcovid19characteristics
AT fakkariafjadijavad acomprehensivereviewofcovid19characteristics
AT farahmandiannavid acomprehensivereviewofcovid19characteristics
AT miresmaeiliseyedmohsen acomprehensivereviewofcovid19characteristics
AT bahreinielham acomprehensivereviewofcovid19characteristics
AT esakandarihanie comprehensivereviewofcovid19characteristics
AT nabiafjadimohsen comprehensivereviewofcovid19characteristics
AT fakkariafjadijavad comprehensivereviewofcovid19characteristics
AT farahmandiannavid comprehensivereviewofcovid19characteristics
AT miresmaeiliseyedmohsen comprehensivereviewofcovid19characteristics
AT bahreinielham comprehensivereviewofcovid19characteristics